At a glance
ClinicalIndex Comparison RecordN/ACompleted· 65 enrolled
Drug / intervention
Probiotic Supplement +1 moredietary
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Double-Blind Placebo-Controlled Trial of a Probiotic Supplement to Reduce the Symptoms of Schizophrenia
In Brief
A clinical study evaluating Probiotic Supplement and Identical-appearing Placebo for Schizophrenia and Schizoaffective Disorder. Completed, enrolled 65 participants across 1 site.
Detailed Summary
The investigators intend to explore the hypothesis that symptoms of schizophrenia may be reduced by the administration of a probiotic supplement when used in addition to standard antipsychotic medications.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSchizophrenia, Schizoaffective Disorder
CountriesUnited States
CollaboratorsStanley Medical Research Institute
Timeline
N/ACompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartAug 2010
First PostedNov 2010
Primary CompletionAug 2012
TodayJul 2026
First PostedNov 17, 2010
Enrollment StartAug 1, 2010
Primary CompletionAug 1, 2012
TodayJul 2, 2026
Enrollment to primary: 2 yearsPosted 15.6 years ago
Interventions
Probiotic Supplementdietary
Probiotic Supplement 1 tablet by mouth daily
Identical-appearing Placebodietary
Probiotic identical placebo 1 tablet by mouth daily